These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23437524)

  • 1. [Effectiveness of the anti-meningococcal vaccine VA-MENGO-BC in the first year of life of Cuban children, 1997-2008].
    Pérez Rodríguez A; Dickinson Meneses F; Rodríguez Ortega M
    Rev Cubana Med Trop; 2011; 63(2):155-60. PubMed ID: 23437524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuban Meningococcal Vaccine VA-MENGOC-BC:30 Years of Use and Future Potential.
    Sierra-González VG
    MEDICC Rev; 2019 Oct; 21(4):19-27. PubMed ID: 32335565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [VA-MENGOC-BC vaccine: its impact on meningococcal disease in children 1-4 years old].
    Pérez Rodríguez A; Meneses FO
    Rev Cubana Med Trop; 1999; 51(3):189-93. PubMed ID: 10887587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
    J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Meningococcal disease and VA-MENGOC BC in minors less than 1 year of age. Cuba, 1983 to 1991].
    Rico Cordeiro O; Jiménez Barreras R; Pereira Colls C
    Rev Cubana Med Trop; 1996; 48(1):34-9. PubMed ID: 9768267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The post-licensing efficacy of VA-MENGOC-BC in children under 6 in Holguín, Cuba. The first year of observation].
    Rico Cordeiro O; Pereira Colls C; Fernández AA
    Rev Cubana Med Trop; 1995; 47(1):59-64. PubMed ID: 9805070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Boulianne N; De Serres G
    Pediatr Infect Dis J; 2011 Jul; 30(7):566-9. PubMed ID: 21326136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal disease from the public health policy perspective.
    Black SB; Plotkin SA
    Vaccine; 2012 May; 30 Suppl 2():B37-9. PubMed ID: 22607897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The epidemiological impact of antimeningococcal B vaccination in Cuba.
    Rodriguez AP; Dickinson F; Baly A; Martinez R
    Mem Inst Oswaldo Cruz; 1999; 94(4):433-40. PubMed ID: 10445998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness of VA-MENGOC-BC in children from 0 to 5 years of age in Cuba. First year of observation].
    Rico Cordeiro O; Bravo González JR; Díaz González M
    Rev Cubana Med Trop; 1994; 46(2):94-8. PubMed ID: 9768243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand.
    Lennon D; Gellin B; Hood D; Voss L; Heffernan H; Thakur S
    Pediatr Infect Dis J; 1992 Aug; 11(8):617-23. PubMed ID: 1523071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis.
    Bettinger JA; Scheifele DW; Halperin SA; Kellner JD; Vanderkooi OG; Schryvers A; De Serres G; Alcantara J
    Vaccine; 2012 Jun; 30(27):4023-7. PubMed ID: 22537988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
    Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life.
    Diez-Domingo J; Planelles-Cantarino MV; Baldo-Torrenti JM; Ubeda-Sansano I; Jubert-Rosich A; Puig-Barbera J; Gutierrez-Gimeno MV
    Pediatr Infect Dis J; 2010 Aug; 29(8):768-70. PubMed ID: 20375851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.